1 / 32

Topoisomerase-II  a Predictive Molecular Marker in Breast Cancer:

Topoisomerase-II  a Predictive Molecular Marker in Breast Cancer:. Konecny G, Jakobson K, Pegram M, Pauletti G, Dandekar U, Morisson J Ramos L. He-Jing Wang, Seelig S, and Slamon DJ . University of California, Los Angeles Vysis Inc., Downers Grove, Illinois.

elina
Télécharger la présentation

Topoisomerase-II  a Predictive Molecular Marker in Breast Cancer:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Topoisomerase-IIa Predictive Molecular Marker in Breast Cancer: Konecny G, Jakobson K, Pegram M, Pauletti G, Dandekar U, Morisson JRamos L. He-Jing Wang, Seelig S,and Slamon DJ University of California, Los AngelesVysis Inc., Downers Grove, Illinois

  2. Predictive Markers in Breast Cancer Role of HER2 as a predictive marker for response to anthracyclines is a matter of debate

  3. HER2 and Response to Anthracyclines Relative Risk of Failure for DFS 0.5 1.0 1.5 p = 0.001 p = 0.74 HER2 + HER2 - PAF vs. PF AC vs. CMF p = 0.15 p = 0.84 HER2 + HER2 - Paik S et al.: JNCI, 1998 and 2000

  4. HER2 and Response to Anthracyclines DFS Hazard Ratio 0.5 1.0 1.5 p = 0.29 p = 0.11 HER2 + HER2 - CMF vs. EC CMF vs. FEC p = 0.06 p = 0.61 HER2 + HER2 - Di Leo et al.: Ciin Cancer Res, 2002; Pritchard K: ASCO 2002

  5. In Vitro Sensitivity to Doxorubicin following HER2 Transfection 100% IC50 relative to control MCF-7 MDA-MB 435 MDA-MB-231 BT20 Control cells HER2 transfected cells Pegram M et al.: Oncogene 1998

  6. Predictive Markers in Breast Cancer HER2 could be a surrogate for other markers predicting response to anthracyclines

  7. Comparative Genomic Hybridization Among 38 Breast Cancer Cell lines Forozan F. et al.: Cancer Res, 2001

  8. Comparative Genomic Hybridization Among 38 Breast Cancer Cell lines Forozan F. et al.: Cancer Res, 2001

  9. Chromosome 17q12 - q21 TRAP100 PIP5 HER2 (124kb) ZNFN1A GRB7 MLN51 THRA CDC6 RARA TOPOII 2MB Human Genome Data Base, PubMed Nucleotides

  10. Topoisomerase-II • Amplifications can span large regions of chromosome 17q • Topo-II is close to the HER2 amplicon on chromosome 17q • Topo-II is akey enzyme in DNA replication and a molecular target for Anthracyclines

  11. Questions • Prevalence of Topo-II gene alterations in HER2-positive samples ? • Correlation between the gene alteration and protein expression ? • Are cells with high Topo-II expression more sensitive to anthracyclines ? • Are cells with low Topo-II expression less sensitive to anthracyclines ?

  12. UCLA Study • 300 patients with metastatic breast cancer (MBC) • Anthracycline based chemotherapy for treatment of MBC • 35% HER2 amplification (FISH) • Clinical response data available for the Topo-II subgroups

  13. Topo-II Detection - FISH • 158 kb Topo-II probe, Vysis • SpectrumOrange labeled Topo-II probe • SpectrumGreen chromosome 17 centromeric alpha-satellite probe (chr.17cen) • Topo-II /chr.17cen ratio to correct for chromosome 17 polysomy • Count 100 nuclei and calculate the mean ratio of Topo-II/chr.17cen

  14. Normal ratio < 2

  15. Topo-II Amplification Cep17 DAPI Topo-II

  16. Topo-II Deletion Cep17 DAPI Topo-II

  17. Normal Topo-II Cep17 Ratio Cep17 DAPI Topo-II

  18. UCLA Study • 64/100 HER2+ patients have been evaluated • 64 HER2+ • No Topo-II alterations among HER2- patients 16 (25%) Topo Ampl. 29 (45.3%) Normal 19 (29.7%) Topo Deletion

  19. Topo-II Gene Alterationsin Breast Cancer • 136 primary breast cancers • 70/136 HER2 amplification (FISH) • 70 HER2+ • No alterations in HER2-negative samples 29 (41%) Topo Ampl. 11 (16%) Normal 30 (43%) Topo Deletion Jarvinen et al.: Genes, Chromosomes and Cancer, 1999

  20. Correlation Between Topo-II Gene Alterations and Protein Expression Gene amplification - - + + + Protein Gene amplification - - + + + + + Protein Jarvinen et al.: Genes, Chromosomes and Cancer, 1999

  21. EGFR/HER2 Stimulation Upregulates Topo-II Protein Expression NIH77 + EGF NIH82 + EGF NIH77 - EGF NIH82 - EGF Harris LN et al.: Clin Cancer Res.:2001

  22. Influence of Cell Cycle on Topo-II Protein Expression Topo-II expression Topo-II expression relative to DNA levels Stacey DW et al.: Mol. Cell. Biol., 2000

  23. In Vitro Experiments • Increased Topo-II expression is associated with drug sensitivity • Reduced levels with drug resistance

  24. Mechanism of Action • Topo-II is essential for uncoiling of DNA • Topo-II makes double-stranded breaks in DNA • DNA molecules can pass through the break • Topo-II religates the free ends • Anthracyclines freeze religation

  25. Topo-II and Response to Anthracyclines in Breast Cancer Clinical studies: • Most studies are small and underpowered • Many investigators use IHC • Most studies do not investigate the predictive value of Topo-II independent of HER2 overexpression

  26. Topo-II Gene Alterationsin Breast Cancer • 196 patients with MBC • Anthracycline based chemotherapy for First-line treatment of MBC • 32% HER2 amplification (FISH) • 32% HER2+ 34% Topo Ampl. 45% Normal 21% Topo Deletion Isola JJ et al.: Breast Cancer Res. Treat.: 2000

  27. Response Rates in 61 HER2+ Patients p=0.0004 79% 80 70 Topo-IIDeletion 60 Normal 50 35% 40 30 17% Topo-IIAmplified 20 10 0

  28. Topo-II Gene Alterationsin Breast Cancer • 354 primary breast cancers • EC vs. HEC vs. CMF • 21% HER2 amplification (FISH) • 21% HER2+ 38% Topo Ampl. 49% Normal 13% Topo Deletion Di Leo et al.: Ciin Cancer Res, 2002;

  29. DFS in 61 HER2+ Patients Di Leo et al.: Ciin Cancer Res, 2002;

  30. Summary • 30-40% of HER2-positive patients have Topo-IIamplifications and 20-30% Topo-II deletions. • High Topo-IIlevels confer anthracycline sensitivity in vitro. • Preliminary clinical data support this hypothesis. • Confirmatory studies are necessary. • At best, 10% of all breast cancer patients will potentially benefit from using Topo-II as a predictive marker.

More Related